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Abstract: Autoantibodies against several aminoacyl-transfer-RNA
synthetases have been described in patients with myositis; anti-threonyl-
tRNA synthetase (anti-PL-7) is one of the rarest. We describe the clinical
and laboratory characteristics of a cohort of European anti-PL-7 patients,
and compare them with previously reported cases. This multicenter study
of patients positive for anti-PL-7, identified between1984and2011, derives
from the EUMYONETcohort. Clinical and serologic datawere obtained by
retrospective laboratory and medical record review, and statistical analyses
were performed with chi-squared and Fisher exact tests.
Eighteen patients, 15 women, were anti-PL-7 antibody positive.
Median follow-up was 5.25 years (interquartile range, 2.8Y10.7 yr), and
4 patients died. All patients had myositis (12 polymyositis, 5 dermato-
myositis, and 1 amyopathic dermatomyositis), 10 (55.6%) had interstitial
lung disease, and 9 (50%) had pericardial effusion. Occupational expo-
sure to organic/inorganic particles was more frequent in patients with
interstitial lung disease than in the remaining patients (5 of 10 vs. 1 of
7; p = 0.152), although the difference was not significant. Concur-
rent autoantibodies against Ro60 and Ro52 were seen in 8 of 14 (57%)
patients studied. In the literature review the most common manifes-
tations of anti-PL-7 antisynthetase syndrome were interstitial lung dis-
ease (77%), myositis (75%), and arthritis (56%). As in other subsets
of the antisynthetase syndrome, myositis and interstitial lung disease
are common features of the anti-PL-7 antisynthetase syndrome. In ad-
dition, we can add pericarditis as a possible manifestation related to
anti-PL-7 antibodies.
(Medicine 2012;91: 206Y211)
Abbreviations: ANA = antinuclear antibodies, DLCO = diffusing
capacity of the lung for carbon monoxide, DM = dermatomyositis,
FEV1 = forced expiratory volume in 1 second, FVC = forced vital
capacity, ILD = interstitial lung disease, IQR = interquartile range,
PM = polymyositis.
INTRODUCTION
Idiopathic inflammatory myopathiesVpolymyositis (PM) anddermatomyositis (DM)Vare systemic autoimmune diseases
characterized by skeletal muscle inflammation, but other or-
gans are frequently involved such as skin in dermatomyositis
and lungs and heart in both polymyositis and dermatomyositis.
Up to 56% of patients with myositis are positive for various
autoantibodies, which can be classified as associated (present
in other rheumatic disorders) or specific (positive predomi-
nantly in myositis).4 Among the myositis-specific autoantibodies
group, antisynthetase antibodies are the most commonly found,
and are directed against aminoacyl-transfer-RNA synthetases, a
group of cytoplasmic enzymes that catalyze binding of an ami-
no acid to its cognate tRNA, a necessary step in the formation
of polypeptides. To our knowledge, 8 autoantibodies against
different synthetases have been described to date: anti-Jo-1, anti-
PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS, anti-YRS, and anti-
Zo.1,5,11,14,21,24,28
The clinical profiles associated with these various anti-
synthetase antibodies, in particular anti-Jo-1, have been inves-
tigated previously.7,22 The main associated clinical features
are myositis, interstitial lung disease (ILD), arthritis, fever,
Raynaud phenomenon, and mechanic’s hands, comprising the
‘‘antisynthetase syndrome.’’ In addition, individual autoantibody
specificities may be associated with distinctive clinical features.
Non-Jo-1 antisynthetase antibodies seem to be markers of hypo-
myopathic forms with prominent lung involvement.10,13,15 Few
studies have focused on the clinical manifestations of patients
with anti-PL-7, an antibody directed against threonyl-tRNA syn-
thetase.12,25,33 We conducted the current study to investigate the
clinical and laboratory profiles of patients with anti-PL-7 anti-
body in a large cohort of European patients, and to compare them
with previously reported cases.
PATIENTS AND METHODS
Patients
Patients positive for anti-PL-7 recorded during the period
of 1984 to 2011 were identified from the laboratory databases or
rheumatology clinics of the following university hospitals: Vall
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d’Hebro´n General Hospital, Universitat Auto`noma de Barcelona,
Barcelona, Spain; Medical and Health Science Center, University
of Debrecen, Debrecen, Hungary; Karolinska University Hospi-
tal, Stockholm, Sweden; Institute of Rheumatology, Charles Uni-
versity, Prague, Czech Republic; and Imperial College Healthcare
NHS Trust, London, United Kingdom. In total 964 myositis
patients were identified.
Clinical data were obtained by a retrospective review of
medical records. Clinical findings included the presence or ab-
sence of inflammatory myopathy, ILD, arthritis, Raynaud phe-
nomenon, mechanic’s hands, fever, skin rash, heart involvement,
history of smoking and environmental exposures related to
profession, and other relevant clinical features. The diagnosis of
dermatomyositis and polymyositis was based on the criteria of
Bohan and Peter,2,3 and only patients with definite or probable
disease were included. The Sontheimer criteria27 were used to
diagnose amyopathic dermatomyositis. The diagnosis of ILD
was established when any of the following conditions were pres-
ent: interstitial infiltrates on chest radiography or high-resolution
computed tomography (ground-glass opacities, honeycombing,
fibrosis, and/or interstitial thickening) and/or a restrictive pattern
on pulmonary function testing (forced vital capacity EFVC^ G80%,
forced expiratory volume in 1 second EFEV1^ G70%, diffusing
capacity of the lung for carbon monoxide EDLCO^ G75%), and/or
positive histology. Pericardial effusion was assessed by transtho-
racic echocardiography.
Autoantibody Analyses
Myositis-specific and -associated autoantibodies were
identified by line immunoassay (Myositis Profile Euroline,
Euroimmun, Lu¨beck, Germany) or RNA and protein immuno-
precipitation assay. Anti-PL-7 antibodies were confirmed by at
least 2 of the following techniques: ELISA, line immunoassay
(Myositis Profile Euroline), or RNA and protein immunoprecip-
itation assay. To exclude false-positive cases, we included only
patients who repeatedly tested positive for anti-PL-7. Antinuclear
antibodies (ANA) and extractable nuclear antigens were assessed
by ELISA. Serum samples were obtained after patients provided
oral informed consent.
Human Leukocyte Antigen Typing
Human leukocyte antigen (HLA) class II was detected with
a sequence-specific primer and sequence-specific oligonucleo-
tide polymerase chain reaction technique.
Ethics
The institutional review boards of all the participating
centers approved the study.
Literature Review
We searched the English-language literature in the PubMed
database (National Library of Medicine, Bethesda, MD) for re-
lated articles published up toMarch 2011, using the following key
words: ‘‘PL-7 antibody,’’ ‘‘anti-PL-7,’’ ‘‘anti-threonyl-tRNA syn-
thetase,’’ and ‘‘antisynthetase syndrome.’’
Statistical Analyses
Qualitative data are presented as numbers and percentage,
and quantitative data as themedian and interquartile range (IQR).
Association between the presence of anti-PL-7 antibodies and
qualitative variables was assessed using the chi-squared and
Fisher exact tests. All statistical analyses were performed with
SPSS 13.0 software (SPSS, Chicago, IL). Significance was set
at a p value of less than 0.05.
RESULTS
Clinical Features
Eighteen anti-PL-7-positive patients were identified out of
964 patients tested from the contributing centers (1.87%). The
median age at diagnosis was 52.5 years (IQR, 40Y58.8 yr), and
there was a predominance of women (15 patients, 83%). Eight
(44.4%) patients were current or former smokers. PM was diag-
nosed in 12 (66.7%) patients, DM in 5 (27.8%), and amyopathic
DM in 1 (5.6%) patient. Two patients had overlap syndromes:
1 patient with DM met the criteria for rheumatoid arthritis, with
positive testing for rheumatoid factor and anticyclic citrullinated
peptide, and the other had PM and Sjo¨gren syndrome.
Clinical features of the 18 patients are summarized in
Table 1. Twelve (66.7%) patients had arthritis. Ten (55.6%)
patients had ILD. Fever attributed to the disease was present in
10 (55.6%) patients, and Raynaud phenomenon in 11 (61.1%).
Nine (50%) patients had pericardial effusion with no apparent
underlying cause (for example, heart failure). Two of them de-
veloped massive effusion with pericardial tamponade: 1 resolved
with medical treatment (glucocorticoids), and the other required
pericardiocentesis. Mechanic’s hands were reported in 5 (27.8%)
patients. Only 1 patient had a malignant disease, breast cancer,
which was diagnosed 4 years after the PM diagnosis.
The onset of ILD was before the start of myositis in 2 cases,
at the same time as myositis in 7, and after myositis in 1. In all
10 patients with ILD, pulmonary involvement was confirmed
by high-resolution computed tomography, which showed various
radiologic patterns. Signs of fibrosis were documented in 9 of the
10 patients, interstitial thickening in 5, honeycombing in 4, and
ground-glass opacities in 4.
Pulmonary function tests were carried out in 5 cases and
showed a restrictive pattern with a median FVC at diagnosis
of 61% (IQR, 57%Y75.5%) and FEV1 of 69.5% (IQR,
51.4%Y74.3%). Transbronchial biopsy in 1 patient and autopsy
findings in another disclosed alveolitis in both cases. One patient
required orotracheal intubation due to respiratory failure caused
by severe ILD, with later recovery.
Six patients in the cohort had been exposed to various
organic/inorganic particles at work, including 2 factory workers,
a plumber, a farmer, a cleaning worker, and a miner (uranium
mines). All but 1 (a factory worker) had underlying ILD, which
appeared before or at the same time as myositis. Nonetheless,
there was no significant association between working expo-
sure and ILD (5 of 10 with ILD vs. 1 of the 7 remaining patients,
p = 0.152).
The median follow-up was 5.25 years (IQR, 2.8Y10.7 yr),
and 4 patients died. The cause of death was attributed to pro-
gression of ILD in 2 patients (1 complicated with Pneumocystis
jiroveci infection), acute myocardial infarction in 1 patient, and
sepsis secondary to Salmonella species in 1 patient.
The following treatment options were used either alone
or in combination: glucocorticoids (100%), azathioprine (33%),
cyclophosphamide (33%), methotrexate (22%), immunoglobu-
lins (16%), and cyclosporine (5%). Four patients were treated
with glucocorticoids alone, 5 patients with glucocorticoids plus
1 immunosuppressive drug, 7 patients with glucocorticoids and
2 immunosuppressive drugs, and 2 patients with 3 or more im-
munosuppressive drugs (see Table 1).
Antibody Profile and HLA
Seven patients were ANA-positive, with titers ranging from
1/320 to 1/2560. Anti-Ro/SSA antibody was found in 4 patients,
and anti-Ro52 antibody in 5 patients. Anti-La/SSB was found
in 2 patients, and anti-PM-Scl, anti-RNP, and anticardiolipin
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antibodies were found in 1 patient each. Rheumatoid factor was
positive in 2 cases, 1 of whom additionally had anticyclic cit-
rullinated peptide. HLA typing was performed in 13 patients.
DRB haplotype is shown in Table 2. The most common hap-
lotypes were DRB1*04 in 6 patients and DRB1*03 in 5 patients.
Only 2 of the patients with ILD showed the DRB1*03 allele.
Literature Review
We identified 54 additional cases of anti-PL-7 antisynthe-
tase syndrome in the literature. The main clinical manifestations
in the overall group of 72 patients (present cohort and reported
cases) were ILD in 56 (77.8%) patients and myositis in 54 (75%).
The prevalence of other signs and symptoms of anti-PL-7 anti-
synthetase syndrome is summarized in Table 3.
DISCUSSION
Antisynthetase syndrome, to our knowledge first described
in 1990, is recognized by its characteristic clinical manifestations
associated with the presence of an anti-tRNA synthetase anti-
body.20 Anti-Jo-1 is the most frequent, followed by anti-PL-12
and anti-PL-7. It has been suggested that in addition to a common
core syndrome, different clinical features may be associated with
different antisynthetase antibodies, but the scarcity of published
studies, most of which are case reports, precludes any definitive
conclusions in this regard.16
In the present study, we analyzed the clinical and labora-
tory features of a series of anti-PL-7-positive patients from 5
European countries. In common with other reported antisyn-
thetase syndromes, myositis and ILD were the most frequent
manifestations of anti-PL-7-associated syndrome, and these com-
mon features were confirmed in a review of all cases published
TABLE 1. Clinical and Serologic Features of 18 European Patients With Antisynthetase (PL-7) Syndrome
Patient
Age/Sex
(yr)
Smoking
Status Job Myositis AR Ray MH Fever ILD PD Ab Therapy Death
1 65/F No Shop worker DM Yes Yes Yes No Yes Yes ANA, RF GC + CP+
MTX+AZA
Yes; sepsis
2 52/F Yes Administration DM Yes No Yes No No Yes Ro, Ro52 GC+AZA+IG
3 56/F No Housewife ADM Yes No Yes No Yes Yes ANA, Ro52 GC+CP+AZA
4 37/F No - DM No No No Yes No Yes ANA, Ro GC+CYS+IG
5 45/F No Cleaning
worker
PM Yes Yes No Yes Yes Yes ANA GC+AZA Yes; MI
6 40/F Yes Administration PM No Yes No No No No PM-Scl GC
7 55/F No Administration PM Yes Yes No No No No - GC
8 32/F No Administration PM Yes Yes No No No No RNP GC
9 40/F No Waiter PM Yes No No Yes No No Ro, La GC+MTX
10 38/F No Toy factory PM Yes Yes Yes No No Yes Ro, La GC+CP+AZA
11 55/F No Farmer PM No Yes No No Yes No ANA, ACA GC+CP
12 53/F Yes Car factory PM Yes Yes No Yes Yes Yes - GC+MTX
13 62/M Yes Plumber PM No Yes Yes Yes Yes Yes ANA, Ro52,
CL
GC+MTX
14 61/M Yes Miner
(uranium)
PM No No No Yes Yes No Ro52 GC
15 46/M Yes Song writer PM No No No Yes Yes No - GC+AZA+MF
16 58/F Yes Administration DM Yes Yes No Yes No NA RF, CCP GC+AZA+
MTX
17 69/F No Administration PM Yes Yes No Yes Yes Yes - GC+CP+MTX Yes; ILD
18 40/F Yes Administration DM Yes No No Yes Yes No ANA, Ro52 GC+CP+AZA+
MTX+IG
Yes; ILD
Abbreviations: Ab = antibodies, ADM = amyopathic dermatomyositis, AR = arthritis, AZA = azathioprine, CCP = cyclic citrullinated peptide,
CL = cardiolipin, CP = cyclophosphamide, CYS = cyclosporin, GC = glucocorticoids, IG = intravenous immunoglobulin, MF = mycophenolate,
MH = mechanic’s hands, MI = myocardial infarction, MTX = methotrexate, NA = not available, PD = pericardial disease, RF = rheumatoid factor,
Ray = Raynaud phenomenon.
TABLE 2. Immunogenetic Profile (HLA Class II Alleles)
of 18 Patients With Antisynthetase (PL-7) Syndrome
Patient HLA-DRB1
1 -
2 HLA-DRB1*03,04
3 HLA-DRB1*04,15
4 HLA-DRB1*12
5 -
6 HLA-DRB1*03
7 HLA-DRB1*07,*07
8 HLA-DRB1*04,*11
9 HLA-DRB1*03;*04
10 HLA-DRB1*11
11
12 HLA-DRB1*04,*07
13 HLA-DRB1*03,*11
14 -
15 -
16 HLA-DRB1*01,*11
17 HLA-DRB1*03,*04
18 HLA-DRB1*08,*15
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to date in the literature. An unexpected finding in the current
cohort was pericardial effusion in half of our cases.
Due to the low patient numbers, few studies have focused
on the clinical and laboratory characteristics of patients with anti-
PL-7 antibodies. The most complete are 2 studies performed in
Japan, comprising 7 and 6 patients, respectively,25,33 and a 2011
report by Hervier et al12 in France with 12 patients. In these
studies, ILD was present in 100% of cases, while myositis ap-
peared in 50%Y86%. In the present series, 6 of 18 patients did
not have diagnosed ILD, and there was a much higher preva-
lence of myositis (all patients had idiopathic inflammatory myo-
pathies except 1, who had amyopathic dermatomyositis). These
results differ to some degree from those of previous studies, in
which the prevalence of myositis in patients with non-Jo-1 anti-
synthetase autoantibodies was lower than in patients with anti-Jo-
1.10,15 However, a pooled analysis of our findings together with
those from all published case reports and series in the litera-
ture7,9,12,17,20,21,25,29,31,33 (72 anti-PL-7-positive patients) showed
that the frequency of ILD and myositis (77.8% and 75%, re-
spectively; see Table 3) does not differ greatly from the clinical
findings in patients with anti-Jo-1. One explanation for the dis-
crepancies between individual studies could be the potential se-
lection bias involved in the study of all rare diseases. In small
series, some clinical manifestations might be overrepresented;
hence to try to overcome these problems, we included a review of
all cases published in the literature, in addition to our own cohort,
and analyzed the pooled data set. Other possible reasons for the
dissimilar results might be the racial/ethnic or genetic background
of the patients, a different referral pattern (pulmonary, rheuma-
tology, or internal medicine specialists), and the fact that in many
cases, only patients with clinically evident myositis were tested
for antisynthetase antibodies.
Little is known about the etiopathogenesis of the antisyn-
thetase syndrome, or for that matter, of myopathies in general.
According to some authors, an unknown trigger (for example,
viral infection) might enter the respiratory tract and lead to a
conformational modification of aminoacyl-tRNA synthetase in
the pulmonary alveoli. This could result in production of auto-
antibodies against the synthetase enzyme; this immune response
(antibodies and specific T cells) would spread to other internal
organs such as muscle and joints.18,19 An interesting factor that
should be investigated in well-designed studies is the contribu-
tion of organic/inorganic dust inhalation at work, which could be
another etiologic trigger of autoimmunity. There has been some
evidence supporting the idea of environmental exposure to
antigens as an initial step in the pathogenesis of antisynthetase
syndrome.30 In the current series, 6 patients had been occu-
pationally exposed to different organic/inorganic particles and
all but 1 had ILD. Nonetheless, statistical significance was not
achieved for this factor, probably because of the small number
of patients studied.
It is noteworthy that 9 of 18 patients in the current series
had pericardial effusion. In the study by Hervier et al,12 4 of 12
(33%) patients with anti-PL-7 had pericardial effusion, and 3
other single cases have been reported in different studies.17,21,33
Pericarditis is, compared to systemic lupus erythematosus, infre-
quent in patients withmyositis. The reason patients with anti-PL-7
develop pericardial disease is unknown. It can be speculated that
anti-PL-7 antibodies act against certain antigens in pericardial
tissue, and thereby lead to pericardial inflammation. Never-
theless, some cases of pericarditis have also been reported in
patients with anti-Jo-1.6,23 In a study and a review of literature by
Schmidt et al,26 they found a prevalence of 18% of pericarditis in
a total of 231 anti-Jo-1 patients, and we cannot exclude that
pericarditis is underestimated in myositis patients because of low
physical function due to muscle and lung involvement.
Other relevant observations can be drawn from this study.
First, it seems that clinical heterogeneity is a feature of the anti-
synthetase syndrome, irrespective of the autoantibody implicated.
The results from the pooled analysis indicate that although anti-
synthetase syndrome can present with a single clinical mani-
festation (for example, myositis, ILD, Raynaud phenomenon,
arthritis, mechanic’s hands), the most common features are myo-
sitis, ILD, and arthritis. The frequency of these symptoms is
similar to that seen in patients with anti-Jo-1 antibodies. As for the
prognosis of antisynthetase syndrome, which is currently poorly
defined, ILD seems to be the major cause of death. It has been
suggested that ILD associated with antisynthetase syndrome may
have a better prognosis than antibody-negative ILD,8 but this has
yet to be confirmed. As was seen in the current study and 1
previously reported study,12 ILD in patients with antisynthetase
syndrome can be aggressive and refractory to treatment. It has
been reported that coexisting Jo-Ro antibodies may predict more
severe ILD,32 but only 1 of our patients who died of ILDwas anti-
Ro52-positive. Further study of lung disease in larger antisyn-
thetase syndrome cohorts is needed to elucidate these findings.
TABLE 3. Main Characteristics of Patients With Antisynthetase (PL-7) Syndrome, Previous and Present Reports
Anti-PL-7 Report
(First Author, Ref.) No. of Patients Myositis (No.) ILD (No.) Arth (No.) Ray (No.) MH (No.) Fever (No.) PE (No.)
Hervier12 12 6 12 4 1 4 8 4
Sato25 7 6 7 6 4 2 4 -
Fischer9 7 3 7 - - - - -
Yamasaki33 6 4 6 3 2 - - 1
Mathews21 5 4 1 3 2 - - 1
Dugar7 4 3 2 1 2 1 1 -
Marguerie20 4 3 3 4 4 - - -
Targoff 29 4 4 3 4 1 - - -
Lega17 3 1 3 2 1 1 - 1
Troyanov31 2 2 2 1 1 - - -
Labirua-Iturburu (PR) 18 18 10 12 11 5 10 9
Total, no. (%) 72 54 (75) 56 (77.8) 40 (55.6) 29 (40.3) 13 (18) 22 (30.5) 16 (22.2)
Abbreviations: Arth = arthritis/arthralgia, MH = mechanic’s hands, PE = pericardial effusion, PR = present report, Ray = Raynaud phenomenon.
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One limitation of the present study is its retrospective na-
ture and the fact that complete data sets were not available for
all patients. Not all patients underwent pulmonary function tests
or high-resolution computed tomography; hence, asymptomatic
ILD could be more prevalent in our cohort than our results
suggest. In addition, a heterogeneous referral pattern could have
led to both over- and underdiagnosis of some clinical features.
Lastly, the small sample size due to the relative rarity of the syn-
drome probably contributed to a lack of statistical power in some
of the comparisons.
In conclusion, our study of a European cohort of anti-PL-7
patients identified myositis as the most frequent clinical mani-
festation, with ILD being less prevalent than has been previously
reported. Nevertheless, when these manifestations were evalu-
ated in all the cases reported to date, including those from the
present study, their prevalence did not vary greatly from the rates
reported for other antisynthetase antibody syndromes. Occupa-
tional exposure should be taken into account in these patients,
because environmental antigens could contribute to triggering
the immune response and the development of the disease. The
unexpected high percentage of patients with pericardial effusion
in our cohort is a novel finding and needs to be confirmed in fu-
ture series. It may be a characteristic of anti-PL-7 antisynthetase
syndrome, which could warrant a recommendation of routine
transthoracic echocardiography in patients presenting with this
serotype.
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